Aviva’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$203M Buy
404,389
+20,387
+5% +$9.79M 0.3% 64
2026
Q1
$189M Sell
384,002
-22,163
-5% -$12M 0.32% 57
2025
Q4
$235M Sell
406,165
-15,042
-4% -$8.51M 0.4% 39
2025
Q3
$204M Sell
421,207
-4,895
-1% -$2.28M 0.37% 42
2025
Q2
$173M Buy
426,102
+157,889
+59% +$66M 0.36% 45
2025
Q1
$133M Buy
268,213
+25,951
+11% +$14.1M 0.32% 57
2024
Q4
$126M Sell
242,262
-54,873
-18% -$30.2M 0.33% 51
2024
Q3
$184M Sell
297,135
-57
-0% -$33.7K 0.48% 35
2024
Q2
$164M Buy
297,192
+28,430
+11% +$16.3M 0.46% 33
2024
Q1
$156M Sell
268,762
-5,419
-2% -$3.04M 0.51% 31
2023
Q4
$146M Sell
274,181
-18,762
-6% -$9.08M 0.52% 33
2023
Q3
$148M Sell
292,943
-39,431
-12% -$21M 0.62% 30
2023
Q2
$173M Buy
332,374
+119,428
+56% +$64.4M 0.71% 26
2023
Q1
$123M Sell
212,946
-19,830
-9% -$11.2M 0.56% 19
2022
Q4
$128M Buy
232,776
+35,603
+18% +$18.9M 0.63% 20
2022
Q3
$100M Sell
197,173
-1,018
-0.5% -$570K 0.58% 17
2022
Q2
$108M Buy
198,191
+9,230
+5% +$5.08M 0.57% 21
2022
Q1
$112M Sell
188,961
-62,266
-25% -$35.8M 0.56% 25
2021
Q4
$168M Buy
251,227
+10,720
+4% +$6.69M 0.7% 21
2021
Q3
$137M Sell
240,507
-933
-0.4% -$512K 0.61% 28
2021
Q2
$122M Sell
241,440
-25,658
-10% -$12.1M 0.53% 32
2021
Q1
$122M Sell
267,098
-43,567
-14% -$20.8M 0.6% 29
2020
Q4
$145M Sell
310,665
-1,262
-0.4% -$592K 0.75% 21
2020
Q3
$138M Sell
311,927
-8,258
-3% -$3.41M 0.81% 21
2020
Q2
$116M Sell
320,185
-53,240
-14% -$17.8M 0.72% 26
2020
Q1
$106M Sell
373,425
-4,778
-1% -$1.51M 0.78% 20
2019
Q4
$123M Buy
378,203
+9,191
+2% +$2.79M 0.74% 25
2019
Q3
$107M Buy
369,012
+48,483
+15% +$13.9M 0.73% 30
2019
Q2
$94.1M Buy
320,529
+35,910
+13% +$9.89M 0.65% 33
2019
Q1
$77.9M Buy
284,619
+284
+0.1% +$70.7K 0.52% 48
2018
Q4
$63.6M Sell
284,335
-21,293
-7% -$5M 0.47% 50
2018
Q3
$74.6M Sell
305,628
-9,585
-3% -$2.21M 0.41% 62
2018
Q2
$65.3M Buy
315,213
+47,953
+18% +$10.2M 0.39% 61
2018
Q1
$55.2M Sell
267,260
-18,556
-6% -$3.89M 0.34% 76
2017
Q4
$54.3M Sell
285,816
-28,797
-9% -$5.52M 0.31% 79
2017
Q3
$59.5M Buy
314,613
+6,939
+2% +$1.26M 0.32% 73
2017
Q2
$53.7M Buy
307,674
+820
+0.3% +$138K 0.3% 74
2017
Q1
$47.1M Sell
306,854
-13,894
-4% -$2.12M 0.27% 91
2016
Q4
$45.3M Buy
320,748
+39,568
+14% +$5.83M 0.27% 87
2016
Q3
$44.7M Buy
281,180
+17,495
+7% +$2.7M 0.28% 83
2016
Q2
$39M Buy
263,685
+41,827
+19% +$6.17M 0.27% 85
2016
Q1
$31.4M Buy
221,858
+3,755
+2% +$503K 0.23% 94
2015
Q4
$30.9M Sell
218,103
-1,377
-0.6% -$184K 0.23% 94
2015
Q3
$26.8M Sell
219,480
-4,754
-2% -$619K 0.22% 107
2015
Q2
$29.1M Buy
224,234
+11,070
+5% +$1.44M 0.21% 117
2015
Q1
$28.6M Buy
213,164
+49,361
+30% +$6.36M 0.2% 116
2014
Q4
$20.5M Sell
163,803
-470
-0.3% -$57.1K 0.16% 151
2014
Q3
$20M Buy
164,273
+870
+0.5% +$106K 0.16% 152
2014
Q2
$19.3M Buy
163,403
+560
+0.3% +$65.9K 0.15% 172
2014
Q1
$19.6M Buy
162,843
+20,360
+14% +$2.42M 0.16% 159
2013
Q4
$15.9M Buy
142,483
+5,423
+4% +$539K 0.13% 186
2013
Q3
$12.6M Buy
137,060
+27,679
+25% +$2.5M 0.11% 220
2013
Q2
$9.26M Buy
+109,381
New +$9.11M 0.09% 246

Other funds holding TMO

Aviva's TMO Position: Q2 2026 in Review

Aviva increased its Thermo Fisher Scientific (TMO) stake by 5.3% in Q2 2026, buying an estimated $9.79M and bringing the position to 404,389 shares worth $203M. The position accounts for 0.3% of the portfolio, ranked #64.

Aviva first reported a position in TMO in Q2 2013 and has held it in 53 quarters since. The position peaked at $235M in Q4 2025. 2,602 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Aviva held 404,389 shares of Thermo Fisher Scientific worth $203M as of Q2 2026.
  • Aviva bought 20,387 Thermo Fisher Scientific shares in Q2 2026, an estimated $9.79M.
  • Thermo Fisher Scientific made up 0.3% of Aviva's portfolio in Q2 2026, its #64 holding.
  • Aviva first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 53 quarters since.
  • Aviva's Thermo Fisher Scientific position peaked at $235M in Q4 2025.
  • 2,602 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.